Groowe Groowe BETA / Newsroom
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

Satellos Announces Upcoming Oral and Poster Presentations at the 2026 Muscular Dystrophy Association Clinical & Scientific Conference

businesswire.com
MSLE The article announces upcoming presentations at a conference, detailing scientific data for SAT-3247. While the data is presented, there's no explicit indication of positive or negative market impact or stock performance.

TORONTO--( BUSINESS WIRE)--Satellos Bioscience Inc. (Nasdaq: MSLE, TSX: MSCL) (“Satellos” or the “Company”), a clinical-stage biotechnology company developing life-improving medicines to treat degenerative muscle diseases, today announced that it will present two oral scientific presentations and three posters at the 2026 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference, taking place March 8-11 in Orlando, Florida.

Oral presentations feature data from the completed Phase 1a/b study of SAT-3247 in healthy volunteers and adult patients with Duchenne muscular dystrophy (DMD), as well as new preclinical data evaluating the impact of SAT-3247 in a mouse model of facioscapulohumeral muscular dystrophy (FSHD).

Oral Presentations:

Poster Presentations:

Posters sessions will take place from 10:30 a.m. – 1:30 p.m., 4 – 4:30 p.m., 6 – 8 p.m. on Tuesday, March 10 in the conference exhibit hall.

Full details from the scientific presentations and posters will follow in a future press release and will be available on the Events and Presentations page of the Satellos website.

For more information on the 2026 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference, visit https://www.mdaconference.org/.

ABOUT SAT-3247

SAT-3247 is a proprietary, oral, small molecule drug being developed by Satellos as a novel treatment to regenerate skeletal muscle that is lost in Duchenne and other degenerative or injury conditions. Satellos is advancing SAT-3247 as a potential treatment for DMD, independent of dystrophin and regardless of exon mutation status.

ABOUT SATELLOS BIOSCIENCE INC.

Satellos is a clinical-stage drug development company focused on restoring natural muscle repair and regeneration in degenerative muscle diseases. Through its research, Satellos has developed SAT-3247, a first-of-its-kind, orally administered small molecule drug designed to address deficits in muscle repair and regeneration. SAT-3247 targets AAK1, a key protein that Satellos has identified as capable of helping restore muscle stem cell signaling that is disrupted in DMD. By addressing the loss of dystrophin-dependent cues, SAT-3247 may re-establish the signals that support effective muscle regeneration. SAT-3247 is currently in clinical development as a potential disease-modifying treatment, initially for DMD. Satellos is also working to identify additional muscle diseases or injury conditions where restoring muscle repair and regeneration may have therapeutic benefit and represent future clinical development opportunities. For more information, visit www.satellos.com.